UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)

BRICKELL BIOTECH, INC.

(Name of Issuer)

Common stock, par value \$0.01 per share

(Title of Class of Securities)

10802T105

(CUSIP Number)

Robert B. Brown c/o Brickell Biotech, Inc. 5777 Central Avenue, Suite 102 Boulder, CO 80301 Tel. (720) 565-4755

with copies to:

Anna T. Pinedo Mayer Brown LLP 1221 Avenue of the Americas New York, NY 10020 Tel. (212) 506-2275 Fax (212) 849-5767

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 14, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. \Box

1	NAME OF REPORTING PERSON. Palisade Concentrated Equity Partnership II, L.P.					
	Palisade Conc	entrate	d Equity Partnership II, L.P.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
_	(a) □ (b) □					
	(-)					
3	SEC USE ONLY					
4	booker of forest (openions)					
00						
5	5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)					
		ISCLO	Sold of Edold I RoceEdd Robins I Regulated in Regulation (1) of the Indian Edol (1) of the			
6		TIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware					
		7	SOLE VOTING POWER			
		/	980.030 shares			
NUM	BER OF		760,000 shares			
	ARES	8	SHARED VOTING POWER			
BENEF	TCIALLY		1,073,374 shares			
	IED BY					
	ACH	9	SOLE DISPOSITIVE POWER			
	ORTING RSON		980,030 shares			
	TTH	10	SHARED DISPOSITIVE POWER			
"	1111	10	1,073,374 shares			
			1,070,071 0114100			
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1,073,374 sha	res				
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
13	PERCENT OF	E CLAS	SS REPRESENTED BY AMOUNT IN ROW (11);			
3.86% ⁽¹⁾		STALLACE TIME (1),				
	5.00/0					
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
PN						
1						

⁽¹⁾ Based on a total of 27,787,081 shares of the Issuer's common stock outstanding as of August 12, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 12, 2020 for the quarter ended June 30, 2020.

-					
1	NAME OF REPORTING PERSON.				
	Palisade Capital Advisors, LLC				
2					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (b) □				
-	and 110n o.				
3	SEC USE ON	LY			
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)			S (SEE INSTRUCTIONS)		
	00				
5		ISCLO	SURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
6		P OR P	LACE OF ORGANIZATION		
	Delaware				
		1			
		7	SOLE VOTING POWER		
			51,781 shares		
	BER OF				
	ARES	8	SHARED VOTING POWER		
	FICIALLY		1,073,374 shares		
	NED BY				
	ACH	9	SOLE DISPOSITIVE POWER		
	ORTING		51,781 shares		
	RSON				
W	/ITH	10	SHARED DISPOSITIVE POWER		
			1,073,374 shares		
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	1,073,374 sha	res			
12	CHECK IF TI	HE AG	GREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);		SS REPRESENTED BY AMOUNT IN ROW (11);			
	3.86%(1)				
14	TYPE OF RE	F REPORTING PERSON (SEE INSTRUCTIONS)			
- '	IA ITTE OF REPORTING PERSON (SEE INSTRUCTIONS)				
L					

⁽¹⁾ Based on a total of 27,787,081 shares of the Issuer's common stock outstanding as of August 12, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 12, 2020 for the quarter ended June 30, 2020.

		PORT	ING PERSON.		
1 1	NAME OF REPORTING PERSON. Dennison T. Veru				
1 1 2	Jennison T. V	eru			
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) 🗆 (b) 🗆				
3 8	SEC USE ON	LY			
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)			S (SEE INSTRUCTIONS)		
	00				
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			SURE OF LEGAL PROCEEDINGS IS REOUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
6 CITIZENSHIP OR PLACE OF ORGANIZATION		OR P	LACE OF ORGANIZATION		
	United States	0111			
1 '	Sinca States				
		7	SOLE VOTING POWER		
		,	41,563 shares		
NUMBE	ED OF		41,505 Shares		
		0	SHARED VOTING POWER		
SHAF		8			
BENEFIC			1,073,374 shares		
OWNE	L				
EAC		9	SOLE DISPOSITIVE POWER		
REPOR			41,563 shares		
PERS					
WIT	TH .	10	SHARED DISPOSITIVE POWER		
			1,073,374 shares		
11 A	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
1	1,073,374 shar	es			
12	CHECK IF TH	IE AG	GREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
1 1					
13 F	PERCENT OF	CLAS	SS REPRESENTED BY AMOUNT IN ROW (11);		
-	3.86% ⁽¹⁾				
	0.80%(-7				
<u> </u>			NO DESCRIPTION OF PROPERTY OF		
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)		NG PERSON (SEE INSTRUCTIONS)			
	N				

⁽¹⁾ Based on a total of 27,787,081 shares of the Issuer's common stock outstanding as of August 12, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 12, 2020 for the quarter ended June 30, 2020.

r .					
1	NAME OF REPORTING PERSON. Palisade Capital Management, L.L.C.				
	Palisade Capi	tal Man	agement, L.L.C.		
2	CHECK THE ADDDODDIATE DOVIE A MEMDED OF A CDOUD (SEE INSTRUCTIONS)				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □				
	(a) 🗆 (b) 🗅				
3	SEC USE ONLY				
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)			S (SEE INSTRUCTIONS)		
	00				
-	CHECK IE D	ICCI O	CLIDE OF LEGAL DROCEFEDRICG IS DECLUDED BUILDING TO ITEMS A(1) A(1)		
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			SURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO TIEMS 2(d) of 2(e)		
6 CITIZENSHIP OR I		P OR P	PLACE OF ORGANIZATION		
	Delaware				
		7	SOLE VOTING POWER		
			0 shares		
	IBER OF				
	IARES	8	SHARED VOTING POWER		
	FICIALLY NED BY		1,073,374 shares		
	NED BY EACH	9	SOLE DISPOSITIVE POWER		
	ORTING	9	0 shares		
	RSON		U SHATES		
	VITH	10	SHARED DISPOSITIVE POWER		
			1,073,374 shares		
11		GREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,073,374 sha	res			
12	CHECK IE TI	III A C	CDECATE AMOUNT BUDOW (1) EVOLUTES CERTARI GUARES (CDE BICTRUCTIONS)		
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		GREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);			SS REPRESENTED BY AMOUNT IN ROW (11):		
	3.86% ⁽¹⁾				
	3.0074				
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
НС					

⁽¹⁾ Based on a total of 27,787,081 shares of the Issuer's common stock outstanding as of August 12, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 12, 2020 for the quarter ended June 30, 2020.

Amendment No. 1 to Schedule 13D

This amendment No. 1 (the "Amendment No. 1") to Schedule 13D relates to the Schedule 13D filed on September 16, 2019 (the 'Original Schedule 13D") by Palisade Concentrated Equity Partnership II, L.P. ("Palisade"), Palisade Capital Advisors, LLC, Dennison T. Veru and Palisade Capital Management, LLC (collectively, the "Reporting Persons") relating to the common stock, par value \$0.01 per share (the "Common Stock"), of Brickell Biotech, Inc. (the "Issuer"). As of the date of this filing, Dennison T. Veru is a member of the Issuer's board of directors. This is the final amendment to the Original Schedule 13D and constitutes an "exiting filing" for the Reporting Persons.

Item 4. Purpose of Transaction

Item 4 of Original Schedule 13D is hereby amended and supplemented with the following information:

"As a result of an increase in the number of the Issuer's issued and outstanding Common Stock, the Reporting Persons' beneficial ownership has decreased below 5% of the Issuer's outstanding shares."

Item 5 Interest in Securities of the Issuer

Item 5 of Original Schedule 13D is hereby amended and supplemented with the following information:

(e) The Reporting Persons ceased to be beneficial owners of more than five percent of the shares of Common Stock on September 14, 2020.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 24, 2020

PALISADE CONCENTRATED EQUITY PARTNERSHIP II, L.P.	/s/ Dennison T. Veru Dennison T. Veru
PALISADE CAPITAL ADVISORS, LLC	/s/ Dennison T. Veru Dennison T. Veru
DENNISON T. VERU	/s/ Dennison T. Veru Dennison T. Veru
PALISADE CAPITAL MANAGEMENT, L.L.C.	/s/ Dennison T. Veru Dennison T. Veru

Directors and Officers of Palisade Capital Management, L.L.C.

Name	Principal Business/ Occupation	
Alison A. Berman	Co-Chairman of the Board of Directors, President & Chief Executive Officer	
Steven E. Berman	Vice Chairman of the Board of Directors	
Jack Feiler	Vice Chairman of the Board of Directors	
Michael Feiler	Director, Managing Director of Private Wealth Management	
Frank Galdi	Chief Risk Officer	
Bradley R. Goldman	General Counsel & Chief Compliance Officer	
Jeffrey D. Serkes	Director, Senior Advisor	
Beata Tannuzzo	Chief Financial Officer	
Dennison T. Veru	Chief Investment Officer & Co-Chairman	
The address for each director and officer is One Bridge Plaza, Suite 695, Fort Lee, NJ 07024		